{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choice&page=2",
    "query": {
      "condition": "Choice",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choice&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T23:05:41.805Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07558733",
      "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HR+ HER2- Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Serabelisib",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Faeth Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-04",
      "completion_date": "2033-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Springfield, Oregon • Nashville, Tennessee",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07558733"
    },
    {
      "nct_id": "NCT02205333",
      "title": "A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Aggressive B-cell Lymphomas"
      ],
      "interventions": [
        {
          "name": "MEDI6469 Monotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI6469 Plus Tremelimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI6469 Plus Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI6469 plus Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-08-13",
      "completion_date": "2016-04-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02205333"
    },
    {
      "nct_id": "NCT04096781",
      "title": "Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AFib Stroke Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Atrial Flutter",
        "Stroke",
        "Cardiac",
        "Heart Failure",
        "Arrhythmia"
      ],
      "interventions": [
        {
          "name": "SDMT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1001,
      "start_date": "2019-12-18",
      "completion_date": "2022-08-17",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • New Orleans, Louisiana • Camden, New Jersey + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04096781"
    },
    {
      "nct_id": "NCT00422669",
      "title": "Optimize RV Selective Site Pacing Clinical Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiac Pacing, Artificial",
        "Cardiac Pacemaker, Artificial"
      ],
      "interventions": [
        {
          "name": "Medtronic Dual-Chamber Pacemaker",
          "type": "DEVICE"
        },
        {
          "name": "Medtronic SelectSecure 3830 Lead",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Cardiac Rhythm and Heart Failure",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2007-01",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 16,
      "location_summary": "Bridgeport, Connecticut • Clearwater, Florida • Hudson, Florida + 13 more",
      "locations": [
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00422669"
    },
    {
      "nct_id": "NCT05748392",
      "title": "3M Veraflo™ Cleanse Choice Complete™ (VFCCC) Clinical Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "WOUNDS INJURIES"
      ],
      "interventions": [
        {
          "name": "Wound and per-wound assessments While using Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Solventum US LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-06-01",
      "completion_date": "2023-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05748392"
    },
    {
      "nct_id": "NCT03152526",
      "title": "CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Interventions",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Miltenyi Biotec B.V. & Co. KG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2017-10-18",
      "completion_date": "2018-03-21",
      "has_results": true,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • Columbus, Ohio",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03152526"
    },
    {
      "nct_id": "NCT03333200",
      "title": "Longitudinal Study of Neurodegenerative Disorders",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "MLD",
        "Krabbe Disease",
        "ALD",
        "MPS I",
        "MPS II",
        "MPS III",
        "Vanishing White Matter Disease",
        "GM3 Gangliosidosis",
        "PKAN",
        "Tay-Sachs Disease",
        "NP Deficiency",
        "Osteopetrosis",
        "Alpha-Mannosidosis",
        "Sandhoff Disease",
        "Niemann-Pick Diseases",
        "MPS IV",
        "Gaucher Disease",
        "GAN",
        "GM1 Gangliosidoses",
        "Morquio Disease",
        "S-Adenosylhomocysteine Hydrolase Deficiency",
        "Batten Disease",
        "Pelizaeus-Merzbacher Disease",
        "Leukodystrophy",
        "Lysosomal Storage Diseases",
        "Purine Nucleoside Phosphorylase Deficiency",
        "Multiple Sulfatase Deficiency Disease"
      ],
      "interventions": [
        {
          "name": "Palliative Care",
          "type": "OTHER"
        },
        {
          "name": "Hematopoetic Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1500,
      "start_date": "2012-01-11",
      "completion_date": "2035-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03333200"
    },
    {
      "nct_id": "NCT05098132",
      "title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Untreated Advanced NSCLC",
        "1st Line NSCLC"
      ],
      "interventions": [
        {
          "name": "STK-012",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synthekine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2022-01-25",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 27,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Fullerton, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05098132"
    },
    {
      "nct_id": "NCT06382636",
      "title": "Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prenatal Disorder"
      ],
      "interventions": [
        {
          "name": "Standard Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2024-05-06",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06382636"
    },
    {
      "nct_id": "NCT06463665",
      "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-squamous Non-small-cell Lung Cancer",
        "Advanced Squamous Non-Small Cell Lung Carcinoma",
        "Metastatic Non-squamous Non Small Cell Lung Cancer",
        "Metastatic Squamous Non-Small Cell Lung Carcinoma",
        "Non-small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Stage III",
        "Non-small Cell Lung Cancer Stage IV",
        "Non-small Cell Lung Cancer Recurrent"
      ],
      "interventions": [
        {
          "name": "Olvimulogene nanivacirepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum chemotherapy: carboplatin or cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC",
          "type": "DRUG"
        },
        {
          "name": "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genelux Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2024-09-26",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-26T23:05:41.805Z",
      "location_count": 15,
      "location_summary": "Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more",
      "locations": [
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06463665"
    }
  ]
}